JO3597B1 - توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي - Google Patents

توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي

Info

Publication number
JO3597B1
JO3597B1 JOP/2014/0268A JOP20140268A JO3597B1 JO 3597 B1 JO3597 B1 JO 3597B1 JO P20140268 A JOP20140268 A JO P20140268A JO 3597 B1 JO3597 B1 JO 3597B1
Authority
JO
Jordan
Prior art keywords
treatment
epigenetic
epigenetic factor
targeting compound
myeloid leukemia
Prior art date
Application number
JOP/2014/0268A
Other languages
English (en)
Inventor
Krupka Christina
Subklewe Marion
B Walter Roland
Original Assignee
Amgen Res Munich Gmbh
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh, Amgen Inc filed Critical Amgen Res Munich Gmbh
Application granted granted Critical
Publication of JO3597B1 publication Critical patent/JO3597B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

يوفر الاختراع الحالي توليفة من عوامل التخلق المتوالي والمركبات ثنائية النوعية التي تستهدف <span dir="LTR">CD33</span> و <span dir="LTR">CD3</span> في علاج ابيضاض الدم النقوي، حيث يتم اختيار عامل التخلق المتوالي من المجموعة التي تتكون من مثبطات هستون دي أسيتيلاز (<span dir="LTR">HDAC</span>)، مثبطات ميثيل ترانسفيراز <span dir="LTR">DNA</span> (<span dir="LTR">DNMT</span>) <span dir="LTR">I</span>، هيدروكسي يوريا، عامل تحفيز مستعمرة المحببات (<span dir="LTR">G-CSF</span>)، مثبطات هستون دي ميثيلاز و <span dir="LTR">ATRA</span> (كل حمض ترانس-ريتينويك). ووفقاً لذلك، يوفر الاختراع تركيبة صيدلانية تشتمل على مركب يستهدف <span dir="LTR">CD33</span> وعامل تخلق متوالي واحد على الأقل وعامل تخلق متوالي للاستخدام في تخفيف، و/أو علاج ابيضاض الدم النقوي، وحيث يزيد عامل التخلق المتوالي من استجابية المريض للمركب المستهدف <span dir="LTR">CD33</span>. علاوة على ذلك، يوفر الاختراع استخدام عامل واحد على الأقل للتخلق المتوالي لزيادة استجابية المريض بابيضاض الدم النقوي للعلاج بالمركب الذي يستهدف <span dir="LTR">CD33</span>، طريقة علاج ابيضاض الدم النقوي، وتشتمل الطريقة على إعطاء عامل واحد على الأقل للتخلق المتوالي ومركب يستهدف <span dir="LTR">CD33</span> لمريض بحاجة إلى ذلك، وصندوق يشتمل على تركيبة صيدلانية للاختراع أو عامل تخلق متوالي للاختراع ومركب ثنائي النوعية يستهدف <span dir="LTR">CD33</span>.
JOP/2014/0268A 2013-09-13 2014-09-14 توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي JO3597B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877714P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
JO3597B1 true JO3597B1 (ar) 2020-07-05

Family

ID=51690351

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0268A JO3597B1 (ar) 2013-09-13 2014-09-14 توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي

Country Status (28)

Country Link
US (1) US10933132B2 (ar)
EP (1) EP3043794B1 (ar)
JP (1) JP6530409B2 (ar)
KR (1) KR102366470B1 (ar)
CN (2) CN111888474A (ar)
AP (1) AP2016009132A0 (ar)
AR (1) AR097648A1 (ar)
AU (2) AU2014320246B2 (ar)
CA (1) CA2923354C (ar)
CL (1) CL2016000564A1 (ar)
DK (1) DK3043794T3 (ar)
EA (1) EA036476B1 (ar)
HK (1) HK1225975A1 (ar)
HU (1) HUE056867T2 (ar)
IL (1) IL278527B (ar)
JO (1) JO3597B1 (ar)
LT (1) LT3043794T (ar)
MA (2) MA46164B1 (ar)
MX (1) MX2016003197A (ar)
MY (1) MY185611A (ar)
NZ (1) NZ716448A (ar)
PH (1) PH12016500434B1 (ar)
SG (2) SG10201801777YA (ar)
SI (1) SI3043794T1 (ar)
TW (1) TWI688401B (ar)
UA (1) UA123199C2 (ar)
WO (1) WO2015036583A2 (ar)
ZA (1) ZA201600528B (ar)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN114652827A (zh) 2015-05-29 2022-06-24 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
WO2017102908A1 (en) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag Improved recombinant production method
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
BR112019019597A2 (pt) * 2017-03-20 2020-04-14 Vaccinex Inc tratamento de câncer com um anticorpo anti-semaforina- 4d em combinação com um agente de modulação epigenética
WO2019103531A1 (ko) * 2017-11-24 2019-05-31 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
KR102090407B1 (ko) * 2017-11-24 2020-03-17 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
US11597933B2 (en) 2017-11-29 2023-03-07 The Trustees Of Columbia University In The City Of New York Combination therapy of lymphoma
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
WO2020025532A1 (en) * 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CN113045664B (zh) 2019-11-28 2023-05-12 尚健单抗（北京）生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
JP2023506458A (ja) 2019-12-09 2023-02-16 北京中因科技有限公司 医薬の製造におけるＣＹＰ４Ｖ２およびＲｄＣＶＦの使用
CN112079934B (zh) 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CN115003802A (zh) 2020-01-02 2022-09-02 宁波茂行生物医药科技有限公司 一种经修饰的免疫效应细胞及其制备方法
CN113481165B (zh) * 2020-07-16 2022-06-03 山东博安生物技术股份有限公司 分泌双特异性t细胞衔接子的car-t及治疗实体肿瘤的应用
CN111733174B (zh) 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
TW202222840A (zh) 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
KR20230147616A (ko) 2021-01-11 2023-10-23 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 황색포도상구균 α-독소를 표적으로 하는 항원 결합단백질 및 이의 응용
KR20230132511A (ko) 2021-01-13 2023-09-15 상하이 후아오타 바이오파마슈티컬 컴퍼니 리미티드 Cd73에 결합하는 단백질 및 이의 용도
CN112630438B (zh) * 2021-03-08 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
JP2024513746A (ja) 2021-03-22 2024-03-27 星濟生物（蘇州）有限公司 ニューモリシンを標的とした抗原結合たんぱく質およびその応用
KR20230166096A (ko) 2021-04-02 2023-12-06 오리셀 테라퓨틱스 컴퍼니 리미티드 Cldn18.2 항원 결합 단백질 및 이의 적용
CN113533729A (zh) * 2021-06-15 2021-10-22 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN115612674A (zh) 2021-07-14 2023-01-17 上海荣瑞医药科技有限公司 一种溶瘤病毒及其用途
CN113461821B (zh) * 2021-09-03 2021-12-28 苏州近岸蛋白质科技股份有限公司 抗cd3人源化抗体
CN114908087B (zh) * 2022-05-07 2024-01-23 四川大学华西医院 一种长循环肾靶向细胞外囊泡的构建及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DE69131780T2 (de) 1991-03-11 2000-11-16 Univ Georgia Res Foundation At Klonierung und expression der luziferase aus renilla
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6146826A (en) 1993-09-10 2000-11-14 The Trustees Of Columbia University In The City Of New York Green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
ATE244758T1 (de) 1998-04-21 2003-07-15 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res (Munich) Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
JP2010509234A (ja) * 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
RU2561457C2 (ru) 2007-04-03 2015-08-27 Эмджен Рисерч (Мьюник) Гмбх Cd3-эпсилон-связывающий домен с межвидовой специфичностью
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
CA2923354A1 (en) 2015-03-19
US10933132B2 (en) 2021-03-02
KR102366470B1 (ko) 2022-02-24
MA46164A1 (fr) 2020-12-31
EA036476B1 (ru) 2020-11-13
IL278527A (ar) 2020-12-31
UA123199C2 (uk) 2021-03-03
HK1225975A1 (zh) 2017-09-22
DK3043794T3 (da) 2021-11-15
EP3043794A2 (en) 2016-07-20
HUE056867T2 (hu) 2022-03-28
MX2016003197A (es) 2016-06-02
LT3043794T (lt) 2021-10-25
CA2923354C (en) 2022-11-29
AR097648A1 (es) 2016-04-06
US20160317657A1 (en) 2016-11-03
AU2014320246A1 (en) 2016-02-18
TW201605473A (zh) 2016-02-16
KR20160058120A (ko) 2016-05-24
MA38898A1 (fr) 2018-01-31
AU2014320246B2 (en) 2020-01-23
ZA201600528B (en) 2021-06-30
TWI688401B (zh) 2020-03-21
AP2016009132A0 (en) 2016-04-30
JP6530409B2 (ja) 2019-06-12
SI3043794T1 (sl) 2021-11-30
JP2016536341A (ja) 2016-11-24
NZ716448A (en) 2022-02-25
SG10201801777YA (en) 2018-04-27
PH12016500434A1 (en) 2016-05-16
PH12016500434B1 (en) 2016-05-16
EP3043794B1 (en) 2021-09-01
MA46164B1 (fr) 2021-04-30
WO2015036583A2 (en) 2015-03-19
IL278527B (en) 2022-07-01
WO2015036583A3 (en) 2015-07-02
AU2020202641A1 (en) 2020-05-14
SG11201600671QA (en) 2016-02-26
MY185611A (en) 2021-05-25
EA201690485A1 (ru) 2016-08-31
CL2016000564A1 (es) 2017-03-24
CN111888474A (zh) 2020-11-06
CN105764505A (zh) 2016-07-13

Similar Documents

Publication Publication Date Title
JO3597B1 (ar) توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
MX2017014299A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
BR112015023001A2 (pt) composição de salto de exon para tratamento de distrofia muscular
BR112015023038A2 (pt) composições para salto de exon para o tratamento da distrofia muscular
EA201591792A1 (ru) Улучшенные композиции для лечения мышечной дистрофии
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
MY162146A (en) Pharmaceutical composition
BR112015014987A2 (pt) Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular
WO2012065139A8 (en) Entpd5 inhibitors
EA201490688A1 (ru) 2-тиопиримидиноны
WO2011153234A3 (en) Methods of inhibiting alu rna and therapeutic uses thereof
MX2014007969A (es) Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
PH12015500069A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
MX2017014300A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
MX2016006966A (es) Derivados de acidos grasos de inhibidores dimericos de la proteina 95 de la densidad post-sinaptica (psd-95).
PH12016502403B1 (en) Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
WO2013123081A3 (en) Use of small molecule inhibitors targeting the interaction between rac gtpase and p67 (phox)
AR109858A1 (es) Métodos que usan inhibidores hdac11
TH162153A (th) สารประกอบไตรไซคลิกที่มีการแทนที่สำหรับการใช้เป็นสารยับยั้ง fgfr